Drug Profile
Research programme: immunological disorder therapeutics - Janssen Biotech
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Carna Biosciences
- Developer Janssen Biotech
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Immunological-disorders in USA
- 11 Jun 2015 Carna Bioscience and Janssen Biotech enter into a license agreement for the development of immunological disorder therapeutics
- 11 Jun 2015 Early research in Immunological disorders in USA (unspecified route)